Answers are grounded in this paper and cite their sources.
Randomized trial indicates suprascapular nerve block reduces adverse events in shoulder surgery patients, suggesting safer analgesic options.
Background: Interscalene brachial plexus block (ISB) is the standard regional analgesic technique for shoulder surgery. Given its adverse event profile, We conducted a randomized controlled trial to compare the analgesic efficacy and postoperative outcomes between the combined suprascapular nerve block (SSnb) and ultrasound-guided selective shoulder anterior capsular block (SHAC; hereinafter referred to as SHAC-SSnb) versus ultrasound-guided ISB. Methods: A total of sixty patients (American Society of Anesthesiologists Score 1-3, age 18-65 years old) scheduled for elective arthroscopic shoulder surgery were randomly assigned to receive either a SHAC-SSnb or ISB. The primary outcomes were pain intensity, at rest and movement, and incidence of adverse events in the first 48 hours postoperatively. Results: During the first 4 hours postoperatively, the 95% confidence intervals for the between-group differences in numerical rating scale (NRS) pain scores crossed the prespecified non-inferiority margin of 1.3 points, indicating that non-inferiority could not be established in the immediate postoperative period. After 8 hours, the distinction was no longer noticeable. Over the course of 48 hours, the disparity between the two groups was minimal, and the confidence interval included 0, thus resulting in a finding of noninferiority. Although opioid consumption was comparable between the groups, the incidence of dyspnea and discomfort related to muscle weakness was higher in the ISB group. Conclusion: SHAC-SSnb was inferior to ISB in the first 4 hours (NRS difference >2.0) but achieved non-inferiority after 8 hours. SHAC-SSnb is non-inferior to ISB in terms of opioid requirement over the 48-hour postoperative period. Patients who received the SHAC-SSnb nerve block had a lower proportion of patient-reported dyspnea and muscle weakness-related discomfort. Limitation: Small sample size and subjective dyspnea assessment warrant cautious interpretation.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: